Jazz Pharmaceuticals
JAZZ
574 hedge funds and large institutions have $10.5B invested in Jazz Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 129 funds opening new positions, 180 increasing their positions, 194 reducing their positions, and 51 closing their positions.
244% more call options, than puts
Call options by funds: $172M | Put options by funds: $50.2M
153% more first-time investments, than exits
New positions opened: 129 | Existing positions closed: 51
31% more capital invested
Capital invested by funds: $8.01B → $10.5B (+$2.48B)
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
14% more funds holding
Funds holding: 503 → 574 (+71)
1.38% more ownership
Funds ownership: 100.17% → 101.55% (+1.4%)
7% less repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 194
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$173M |
| 2 |
Millennium Management
New York
|
+$143M |
| 3 |
Bank of New York Mellon
New York
|
+$110M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$68.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$60.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$126M |
| 2 |
GAM
Goldentree Asset Management
New York
|
-$110M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$87.8M |
| 4 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$68.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$59M |
JAZZ Hedge Fund Activity: Q4 2025 in Review
574 of the 8,269 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2025, worth a combined $10.5B — up 31% from $8.01B a quarter earlier.
Buyers outnumbered sellers: 129 funds opened new JAZZ positions and 51 closed out — a net gain of 78 holders — while 180 added to existing stakes and 194 trimmed.
The largest buyer was Franklin Resources, adding an estimated $173M. The largest seller was JP Morgan Chase, cutting an estimated $126M.
- 574 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2025, up from 503 in Q3 2025.
- Funds reported $10.5B of Jazz Pharmaceuticals stock for Q4 2025, up 31% quarter-over-quarter.
- 129 funds opened new Jazz Pharmaceuticals positions in Q4 2025 and 51 closed out, a net change of +78 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2025 was Franklin Resources, an estimated $173M added.
- The largest Jazz Pharmaceuticals seller in Q4 2025 was JP Morgan Chase, an estimated $126M sold.
Based on aggregated 13F filings for Q4 2025.